Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT7RJY8)

• DTT Name: Xanthine dehydrogenase/oxidase (XDH) DTT Info
• Gene Name: XDH

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[1]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[2]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[3]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[5]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[6]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[7]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[8]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[9]

35 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azaindole derivative 3	DM2EDOM	N. A.	N. A.	Patented	[10]
Azaindole derivative 4	DMCKSJ8	N. A.	N. A.	Patented	[10]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[10]
Azaindole derivative 6	DMJBGHL	N. A.	N. A.	Patented	[10]
Azaindole derivative 7	DMA2JGU	N. A.	N. A.	Patented	[10]
Azole benzene derivative 1	DM0E8YF	N. A.	N. A.	Patented	[10]
Azole benzene derivative 2	DMJG7M6	N. A.	N. A.	Patented	[10]
Azole benzene derivative 3	DMH8Q4T	N. A.	N. A.	Patented	[10]
Azole benzene derivative 4	DMDPHT1	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 1	DMVU9RG	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 10	DMALDZ6	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 11	DMJC4UZ	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 2	DM361J8	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 3	DM2QVHY	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 4	DMHTS5G	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 5	DM10CGB	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 6	DM9DC3U	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 7	DMGNWJD	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 8	DMO8JE7	N. A.	N. A.	Patented	[10]
Fused heterocyclic compound 9	DM25IMA	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-129	DME2IHD	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-130	DM2AVEG	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-131	DMIKTVL	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-132	DMCQB93	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-133	DMXPO6T	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-134	DMY3U7N	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-135	DMVR9TJ	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-136	DM0KR8E	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-137	DML25WY	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-143	DMR7MBY	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-144	DMR43JE	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-145	DMAJRP1	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-155	DM675SX	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-156	DML4AVX	N. A.	N. A.	Patented	[10]
PMID27841045-Compound-157	DM7EXNI	N. A.	N. A.	Patented	[10]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BOF-4272	DMK0PVC	Gout	FA25	Discontinued in Phase 2	[11]
Y-700	DMHFTD0	Gout	FA25	Discontinued in Phase 2	[12]

21 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2,3,4,6-penta-O-galloyl-beta-D-glucose	DMTK650	Discovery agent	N.A.	Investigative	[13]
1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid	DMVTCGP	Discovery agent	N.A.	Investigative	[14]
2-chloro-6(methylamino)purine	DML0S8M	Discovery agent	N.A.	Investigative	[15]
3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine	DMQDKYI	Discovery agent	N.A.	Investigative	[16]
3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole	DMV859W	Discovery agent	N.A.	Investigative	[16]
3,5-di(pyridin-4-yl)-1H-1,2,4-triazole	DM6CBTE	Discovery agent	N.A.	Investigative	[16]
3-O-METHYLQUERCETIN	DMVIZ1S	Discovery agent	N.A.	Investigative	[6]
ACACETIN	DMQOB0X	Discovery agent	N.A.	Investigative	[6]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[6]
Aom-0763	DML1PV3	Gout	FA25	Investigative	[17]
CHRYSOERIOL	DM96ECL	Discovery agent	N.A.	Investigative	[6]
DIHYDROKAEMPFEROL	DM73OTF	Discovery agent	N.A.	Investigative	[6]
Dioxothiomolybdenum(VI) ion	DM93MAB	Discovery agent	N.A.	Investigative	[18]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[19]
FUKUGETIN	DMWF82O	Discovery agent	N.A.	Investigative	[6]
LIQUIRTIGENIN	DM6YSG3	Discovery agent	N.A.	Investigative	[6]
NC-2500	DM45MGZ	Hyperuricaemia	5C55.Y	Investigative	[17]
PERSICARIN	DM3RGPF	Discovery agent	N.A.	Investigative	[6]
ROBINETIN	DMASOWP	Discovery agent	N.A.	Investigative	[6]
SCUTELLAREIN	DMJD03I	Discovery agent	N.A.	Investigative	[6]
Wogonin	DMGCF51	Discovery agent	N.A.	Investigative	[6]

References

• [1] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [2] Clinical pipeline report, company report or official report of Takeda (2009).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [4] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [5] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [6] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [7] Clinical pipeline report, company report or official report of Teijin Pharma.
• [8] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [9] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [10] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [11] Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes. Yakugaku Zasshi. 2001 Dec;121(12):989-94.
• [12] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [13] Pentagalloylglucose, a xanthine oxidase inhibitor from a Paraguayan crude drug, "Molle-i" (Schinus terebinthifolius). J Nat Prod. 1989 Jan-Feb;52(1):210-1.
• [14] Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):879-82.
• [15] The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors. Bioorg Med Chem. 2007 May 15;15(10):3450-6.
• [16] Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646).
• [18] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [19] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.